Haller H - Search Results

1

SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer.

Vázquez-Vicente D, Boria F, Castellanos T, Gutierrez M, Chacon E, Manzour N, Minguez JA, Martin-Calvo N, Alcazar JL, Chiva L; SUCCOR Study Group. Vázquez-Vicente D, et al. Int J Gynecol Cancer. 2024 Feb 5;34(2):203-208. doi: 10.1136/ijgc-2023-004657. Int J Gynecol Cancer. 2024. PMID: 38669163

2

Harnessing technology to improve sleep in frontline healthcare workers: A pilot study of electronic noise-masking earbuds on subjective and objective sleep measures.

Haller HC, Moore SL, Green KK, Johnson RL, Sammel MD, Epperson CN, Novick AM. Haller HC, et al. Sci Prog. 2024 Apr-Jun;107(2):368504241242276. doi: 10.1177/00368504241242276. Sci Prog. 2024. PMID: 38614463 Free PMC article.

3

Alpha1-antitrypsin improves survival in murine abdominal sepsis model by decreasing inflammation and sequestration of free heme.

Zemtsovski JD, Tumpara S, Schmidt S, Vijayan V, Klos A, Laudeley R, Held J, Immenschuh S, Wurm FM, Welte T, Haller H, Janciauskiene S, Shushakova N. Zemtsovski JD, et al. Among authors: haller h. Front Immunol. 2024 Mar 18;15:1368040. doi: 10.3389/fimmu.2024.1368040. eCollection 2024. Front Immunol. 2024. PMID: 38562925 Free PMC article.

4

Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study.

Kollerits B, Gruber S, Steinbrenner I, Schwaiger JP, Weissensteiner H, Schönherr S, Forer L, Kotsis F, Schultheiss UT, Meiselbach H, Wanner C, Eckardt KU, Kronenberg F; GCKD Investigators. Kollerits B, et al. BMC Cancer. 2024 Mar 7;24(1):320. doi: 10.1186/s12885-024-12053-8. BMC Cancer. 2024. PMID: 38454416 Free PMC article.

5

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

Strand V, Jayne DRW, Horomanski A, Yue H, Bekker P, Merkel PA; ADVOCATE Study Group. Strand V, et al. Lancet Rheumatol. 2023 Aug;5(8):e451-e460. doi: 10.1016/S2665-9913(23)00092-9. Epub 2023 Jul 24. Lancet Rheumatol. 2023. PMID: 38251577 Clinical Trial.

6

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.

7

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Brückmann M, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. J Am Soc Nephrol. 2024 Feb 1;35(2):202-215. doi: 10.1681/ASN.0000000000000271. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082486 Free PMC article. Clinical Trial.

8

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Free article. Clinical Trial.

9

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.

10

Endostatin, soluble tumour necrosis factor receptor 1 and soluble tumour necrosis factor receptor 2 cannot predict new onset of microalbuminuria in patients with type 2 diabetes.

Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H, Chatzikyrkou C. Scurt FG, et al. Among authors: haller h. Diabetes Metab Res Rev. 2024 Mar;40(3):e3753. doi: 10.1002/dmrr.3753. Epub 2023 Dec 4. Diabetes Metab Res Rev. 2024. PMID: 38050450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,216 results

Search Page